Evaluation of the prognostic value of systemic inflammation indexes in patients diagnosed with acute coronary syndrome in the emergency department

Background: Cardiovascular diseases progress through inflammation. The aim of this study was to determine the prognostic value of systemic inflammation markers in predicting mortality in patients with acute coronary syndrome (ACS). Methods: This retrospective cross-sectional study included patients who presented at the Emergency Department (ED) with ACS (ST segment elevation myocardial infarction (STEMI)-Myocardial infarction without ST segment elevation (NSTEMI)). Patients who met the study inclusion criteria were selected retrospectively and data were retrieved from the hospital’s automated records system. Systemic inflammatory indexes, including the Systemic inflammation response index (SIRI), Systemic immune-inflammation index (SII) and Aggregate index of systemic inflammation (AISI) were calculated. The patients were grouped according to mortality status and were examined in two groups as STEMI and NSTEMI. Results: The study included 509 patients, comprising 77.2% males and 22.8% females with a mean age of 57.7 years. STEMI was diagnosed in 309 patients and NSTEMI in 200. The most common comorbidities were hypertension in 27.4% of cases, coronary artery disease in 19.4%, and diabetes mellitus in 16.8%. Mortality occurred in 14.3% of the cases. The mean age was found to be significantly higher in the NSTEMI group than in the STEMI group (p < 0.05). The neutrophil value, SII, SIRI and AISI values were significantly higher in the NSTEMI group than in the STEMI group (p < 0.05 for all). The Neutrophil to Lymphocyte ratio (NLR), SIRI, SII and AISI values were also markedly higher in the exitus patient group than in the survivors group (p < 0.05 for all). The multivariate regression analysis results showed that the NLR, SIRI and AISI values had an independent and significant impact on distinguishing survivors from deceased the patients (p < 0.05). Conclusions: Systemic inflammation indexes were found to be significant predictors of mortality in patients with ACS.

STEMI-NSTEMI; Systemic inflammation indexes; Mortality

[1] An epidemic of risk factors for cardiovascular disease. The Lancet. 2011; 377: 527.

[2] Roth GA, Mensah GA, Fuster V. The global burden of cardiovascular diseases and risks: a compass for global action. Journal of the American College of Cardiology. 2020; 76: 2980–2981.

[3] Dhande IS, Doris PA. Genomics and inflammation in cardiovascular disease. Comprehensive Physiology. 2021; 11: 2433–2454.

[4] Baena-Díez JM, Garcia-Gil M, Comas-Cufí M, Ramos R, Prieto-Alhambra D, Salvador-González B, et al. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart. 2018; 104: 119–126.

[5] Wyss CA, Neidhart M, Altwegg L, Spanaus KS, Yonekawa K, Wischnewsky MB, et al. Cellular actors, toll-like receptors, and local cytokine profile in acute coronary syndromes. European Heart Journal. 2010; 31: 1457–1469.

[6] Mehu M, Narasimhulu CA, Singla DK. Inflammatory cells in atherosclerosis. Antioxidants. 2022; 11: 233.

[7] Fiechter M, Ghadri JR, Jaguszewski M, Siddique A, Vogt S, Haller RB, et al. Impact of inflammation on adverse cardiovascular events in patients with acute coronary syndromes. Journal of Cardiovascular Medicine. 2013; 14: 807–814.

[8] Mo X, Li T, Ji G, Lu W, Hu Z. Peripheral polymorphonuclear leukocyte activation as a systemic inflammatory response in ischemic stroke. Neurological Sciences. 2013; 34: 1509–1516.

[9] Zhang C, Liu H, Wang H, Tao Q, Lin X, Ge S, et al. The predictive value of potential hematological biomarkers in acute coronary syndrome. Clinical Laboratory. 2019; 65: 1797.

[10] Kawashima H, Serruys PW, Hara H, Ono M, Gao C, Wang R, et al. 10-year all-cause mortality following percutaneous or surgical revascularization in patients with heavy calcification. JACC: Cardiovascular Interventions. 2022; 15: 193–204.

[11] Li Y, Chen X, Huang L, Lu J. Association between neutrophil-lymphocyte ratio and arterial stiffness in patients with acute coronary syndrome. Bioscience reports. 2019; 39: BSR20190015.

[12] Haybar H, Pezeshki SMS, Saki N. Evaluation of complete blood count parameters in cardiovascular diseases: an early indicator of prognosis? Experimental and Molecular Pathology. 2019; 110: 104267.

[13] Sari I, Sunbul M, Mammadov C, Durmus E, Bozbay M, Kivrak T, et al. Relation of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio with coronary artery disease severity in patients undergoing coronary angiography. Polish Heart Journal. 2015; 73: 1310–1316.

[14] Tangjitgamol S, Udayachalerm W, Wanishsawad C, Kaewwanna W, Ativanichayapong N. Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and coronary artery disease among the physicians. Journal of Inflammation Research. 2024; 17: 59–66.

[15] Yoon GS, Choi SH, Woo SI, Baek YS, Park SD, Shin SH, et al. Neutrophil-to-lymphocyte ratio at emergency room predicts mechanical complications of ST-segment elevation myocardial infarction. Journal of Korean Medical Science. 2021; 36: e131.

[16] Choi DH, Kobayashi Y, Nishi T, Kim HK, Ki YJ, Kim SS, et al. Combination of mean platelet volume and neutrophil to lymphocyte ratio predicts long-term major adverse cardiovascular events after percutaneous coronary intervention. Angiology. 2019; 70: 345–351.

[17] Li Q, Ma X, Shao Q, Yang Z, Wang Y, Gao F, et al. Prognostic impact of multiple lymphocyte-based inflammatory indices in acute coronary syndrome patients. Frontiers in Cardiovascular Medicine. 2022; 9: 811790.

[18] Fan W, Zhang Y, Gao X, Liu Y, Shi F, Liu J, et al. The prognostic value of a derived neutrophil-lymphocyte ratio in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clinical and Applied Thrombosis/Hemostasis. 2021; 27: 10760296211034579.

[19] Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. The role of hematological indices in patients with acute coronary syndrome. Disease Markers. 2017; 2017: 3041565.

[20] Jin Z, Wu Q, Chen S, Gao J, Li X, Zhang X, et al. The associations of two novel inflammation indexes, SII and SIRI with the risks for cardiovascular diseases and all-cause mortality: a ten-year follow-up study in 85,154 individuals. Journal of inflammation research. 2021; 14: 131–140.

[21] Fest J, Ruiter R, Mulder M, Groot Koerkamp B, Ikram MA, Stricker BH, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer—a population-based cohort study. International Journal of Cancer. 2020; 146: 692–698.

[22] Yang YL, Wu CH, Hsu PF, Chen SC, Huang SS, Chan WL, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. European Journal of Clinical Investigation. 2020; 50: e13230.

[23] Dey S, Kashav R, Kohli JK, Magoon R, Walian A, Grover V. Systemic immune-inflammation index predicts poor outcome after elective off-pump CABG: a retrospective, single-center study. Journal of Cardiothoracic and Vascular Anesthesia. 2021; 35: 2397–2404.

[24] Huang J, Zhang Q, Wang R, Ji H, Chen Y, Quan X, et al. Systemic immune-inflammatory index predicts clinical outcomes for elderly patients with acute myocardial infarction receiving percutaneous coronary intervention. Medical Science Monitor. 2019; 25: 9690–9701.

[25] Zhao J, Lv H, Yin D, Zhou X, Zhu H, Guo L, et al. Systemic immune-inflammation index predicts long-term outcomes in patients with three-vessel coronary disease after revascularization: results from a large cohort of 3561 patients. Journal of Inflammation Research. 2022; 15: 5283–5292.

[26] Özkan U, Gürdoğan M, Öztürk C, Demir M, Akkuş ÖF, Yılmaz E, et al. Systemic immune-inflammation index: a novel predictor of coronary thrombus burden in patients with non-ST acute coronary syndrome. Medicina. 2022; 58: 143.

[27] Saylik F, Akbulut T. Systemic immune-inflammation index predicts major cardiovascular adverse events in patients with ST-segment elevated myocardial infarction. Brazilian Archives of Cardiology. 2022; 119: 14–22.

[28] Dziedzic EA, Gąsior JS, Tuzimek A, Kochman W. Blood count-derived inflammatory markers and acute complications of ischemic heart disease in elderly women. Journal of Clinical Medicine. 2023; 12: 1369.

[29] Abohelwa M, Kopel J, Shurmur S, Ansari MM, Awasthi Y, Awasthi S. The Framingham study on cardiovascular disease risk and stress-defenses: a historical review. Journal of Vascular Diseases. 2023; 2: 122–164.

[30] Barbarawi M, Zayed Y, Kheiri B, Barbarawi O, Al-Abdouh A, Dhillon H, et al. Optimal timing of coronary intervention in patients resuscitated from cardiac arrest without ST-segment elevation myocardial infarction (NSTEMI): a systematic review and meta-analysis. Resuscitation. 2019; 144: 137–144.

[31] Chichareon P, Modolo R, Collet C, Tenekecioglu E, Vink MA, Oh PC, et al. Efficacy and safety of stents in ST-segment elevation myocardial infarction. Journal of the American College of Cardiology. 2019; 74: 2572–2584.

[32] Costache II, Mihai BM, Badescu MC. Ischemic heart disease in the context of different comorbidities. Life. 2022; 12: 1558.

[33] D’Ippoliti D, Forastiere F, Ancona C, Agabiti N, Fusco D, Michelozzi P, et al. Air pollution and myocardial infarction in Rome: a case-crossover analysis. Epidemiology. 2003; 14: 528–535.

[34] Ouyang J, Wang H, Huang J. The role of lactate in cardiovascular diseases. Cell Communication and Signaling. 2023; 21: 317.

[35] Liang D, Zhou X, Hong X, Feng X, Shan P, Xie Q, et al. Association between admission lactate levels and mortality in patients with acute coronary syndrome: a retrospective cohort study. Coronary Artery Disease. 2019; 30: 26–32.

[36] Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. Journal of Molecular and Cellular Cardiology. 2021; 161: 98–105.

[37] Goldman EA, Spellman PT, Agarwal A. Defining clonal hematopoiesis of indeterminate potential: evolutionary dynamics and detection under aging and inflammation. Cold Spring Harbor Molecular Case Studies. 2023; 9: a006251.